Cargando…

Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium

Cancer stem cells (CSC) are a potential cause for recurrence, metastasis, and resistance of tumors to different therapeutic modalities like hormonal radiotherapy and chemotherapy. We investigated two CSC markers (NANOG and CD 133) in normal, hyperplastic endometrium and endometrial carcinoma. A tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Kaabi, Methaq, Noel, Khalida, Al-Rubai, Abdal-jabbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852636/
https://www.ncbi.nlm.nih.gov/pubmed/35186145
http://dx.doi.org/10.25122/jml-2021-0206
_version_ 1784653080642453504
author Al-Kaabi, Methaq
Noel, Khalida
Al-Rubai, Abdal-jabbar
author_facet Al-Kaabi, Methaq
Noel, Khalida
Al-Rubai, Abdal-jabbar
author_sort Al-Kaabi, Methaq
collection PubMed
description Cancer stem cells (CSC) are a potential cause for recurrence, metastasis, and resistance of tumors to different therapeutic modalities like hormonal radiotherapy and chemotherapy. We investigated two CSC markers (NANOG and CD 133) in normal, hyperplastic endometrium and endometrial carcinoma. A total of 93 formalin-fixed paraffin-embedded tissue blocks were used for immunohistochemical expression of NANOG and CD133 markers. NANOG expression was detected in 88.37% of endometrial carcinoma cases compared to 15% of the normal proliferative endometrium and 60% of hyperplasia cases. In endometrial carcinoma, high NANOG expression was significantly correlated with high grade, deep myometrial invasion, lymph node metastasis, and high stage with p-values (0.009, 0.005, 0.014, and 0.003, respectively). CD133 was positive in 76.74% of endometrial carcinoma cases, and it showed a significant correlation with deep myometrial invasion, positive lymph node, positive lymphovascular invasion, and high stage (p-values 0.003, 0.001, 0.003, and 0.013, respectively). Normal endometrium showed less expression of CD133 (only 5%) than hyperplasia and endometrial carcinoma with a statistically highly significant difference (p less than 0.0001). Hyperplastic cases with atypia expressed higher CD133 than those without atypia (6 out of 12 versus 3 out of 18). However, this difference was not statistically significant (p-value 0.111). The cancer stem cell markers NANOG and CD 133 are expressed in a high percentage in endometrial carcinoma compared to normal and hyperplasia and their expression is positively correlated with the aggressive behavior of the tumor. High expression of these two markers in apparently normal tissue around the tumor and in hyperplastic conditions with atypia suggests the possibility to use NANOG and CD133 expression as a diagnostic marker distinguishing dysplasia from reactive atypia. Therefore, inhibition of these markers can be a promising method to stop the progression of early cancers.
format Online
Article
Text
id pubmed-8852636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-88526362022-03-01 Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium Al-Kaabi, Methaq Noel, Khalida Al-Rubai, Abdal-jabbar J Med Life Original Article Cancer stem cells (CSC) are a potential cause for recurrence, metastasis, and resistance of tumors to different therapeutic modalities like hormonal radiotherapy and chemotherapy. We investigated two CSC markers (NANOG and CD 133) in normal, hyperplastic endometrium and endometrial carcinoma. A total of 93 formalin-fixed paraffin-embedded tissue blocks were used for immunohistochemical expression of NANOG and CD133 markers. NANOG expression was detected in 88.37% of endometrial carcinoma cases compared to 15% of the normal proliferative endometrium and 60% of hyperplasia cases. In endometrial carcinoma, high NANOG expression was significantly correlated with high grade, deep myometrial invasion, lymph node metastasis, and high stage with p-values (0.009, 0.005, 0.014, and 0.003, respectively). CD133 was positive in 76.74% of endometrial carcinoma cases, and it showed a significant correlation with deep myometrial invasion, positive lymph node, positive lymphovascular invasion, and high stage (p-values 0.003, 0.001, 0.003, and 0.013, respectively). Normal endometrium showed less expression of CD133 (only 5%) than hyperplasia and endometrial carcinoma with a statistically highly significant difference (p less than 0.0001). Hyperplastic cases with atypia expressed higher CD133 than those without atypia (6 out of 12 versus 3 out of 18). However, this difference was not statistically significant (p-value 0.111). The cancer stem cell markers NANOG and CD 133 are expressed in a high percentage in endometrial carcinoma compared to normal and hyperplasia and their expression is positively correlated with the aggressive behavior of the tumor. High expression of these two markers in apparently normal tissue around the tumor and in hyperplastic conditions with atypia suggests the possibility to use NANOG and CD133 expression as a diagnostic marker distinguishing dysplasia from reactive atypia. Therefore, inhibition of these markers can be a promising method to stop the progression of early cancers. Carol Davila University Press 2022-01 /pmc/articles/PMC8852636/ /pubmed/35186145 http://dx.doi.org/10.25122/jml-2021-0206 Text en ©2022 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Al-Kaabi, Methaq
Noel, Khalida
Al-Rubai, Abdal-jabbar
Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium
title Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium
title_full Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium
title_fullStr Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium
title_full_unstemmed Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium
title_short Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium
title_sort evaluation of immunohistochemical expression of stem cell markers (nanog and cd133) in normal, hyperplastic, and malignant endometrium
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852636/
https://www.ncbi.nlm.nih.gov/pubmed/35186145
http://dx.doi.org/10.25122/jml-2021-0206
work_keys_str_mv AT alkaabimethaq evaluationofimmunohistochemicalexpressionofstemcellmarkersnanogandcd133innormalhyperplasticandmalignantendometrium
AT noelkhalida evaluationofimmunohistochemicalexpressionofstemcellmarkersnanogandcd133innormalhyperplasticandmalignantendometrium
AT alrubaiabdaljabbar evaluationofimmunohistochemicalexpressionofstemcellmarkersnanogandcd133innormalhyperplasticandmalignantendometrium